QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Trial details
- Registry ID
- NCT03853317
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as NK-92 [CD16.158V, ER IL-2], (haNK™ for Infusion)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317 | IBRX | Phase 2 | Terminated | 2021-09-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |